Characteristics of patients aged 18 to 60 years undergoing allo-HCT using MAC vs RIC for CML, 2007-2014
| Variable . | MAC (n = 1204) . | RIC (n = 191) . | P . |
|---|---|---|---|
| Follow-up of survivors, median (range), mo | 52 (4-102) | 60 (7-101) | |
| Number of centers | 163 | 76 | |
| Patient related | |||
| Age at transplant, median (range), y | 43 (18-60) | 51 (19-60) | <.001 |
| Age at transplant, y | <.001 | ||
| 18-29 | 212 (18) | 17 (9) | |
| 30-39 | 276 (23) | 21 (11) | |
| 40-49 | 404 (34) | 47 (25) | |
| 50-59 | 312 (26) | 106 (55) | |
| Sex | <.001 | ||
| Male | 722 (60) | 90 (47) | |
| Female | 482 (40) | 101 (53) | |
| KPS, % | <.001 | ||
| 90-100 | 845 (70) | 110 (58) | |
| <90 | 267 (22) | 72 (38) | |
| Missing | 92 (8) | 9 (5) | |
| WHO region | .60 | ||
| Africa | 1 (<1) | 0 | |
| Americas | 1054 (88) | 172 (90) | |
| Eastern Mediterranean | 22 (2) | 0 | |
| Europe | 78 (6) | 10 (5) | |
| Southeastern Asian | 21 (2) | 4 (2) | |
| Western Pacific | 27 (2) | 5 (3) | |
| Missing | 1 (<1) | 0 | |
| Sorror comorbidity index (HCT-CI) | .003 | ||
| 0 | 525 (44) | 64 (34) | |
| 1 | 132 (11) | 27 (14) | |
| 2 | 125 (10) | 25 (13) | |
| 3+ | 246 (20) | 58 (30) | |
| Missing | 176 (15) | 17 (9) | |
| Disease related | |||
| Disease status prior to transplant | .20 | ||
| CP1 | 504 (42) | 92 (48) | |
| AP | 405 (34) | 60 (31) | |
| CP2+ | 278 (23) | 38 (20) | |
| CP, NOS | 17 (1) | 1 (<1) | |
| Prior treatment | .85 | ||
| No | 9 (<1) | 1 (<1) | |
| Yes | 1185 (98) | 189 (99) | |
| Missing | 10 (<1) | 1 (<1) | |
| Use of TKI prior to HCT | .89 | ||
| No | 73 (6) | 11 (6) | |
| Yes | 1121 (93) | 179 (94) | |
| Missing | 10 (<1) | 1 (<1) | |
| TKI used pre-HCT | .11 | ||
| No TKI used | 73 (6) | 11 (6) | |
| Imatinib + dasatinib + nilotinib | 250 (21) | 52 (27) | |
| Imatinib + dasatinib | 295 (25) | 55 (29) | |
| Imatinib + nilotinib | 73 (6) | 13 (7) | |
| Dasatinib + nilotinib | 35 (3) | 8 (4) | |
| Imatinib | 395 (33) | 43 (23) | |
| Dasatinib | 52 (4) | 7 (4) | |
| Nilotinib | 21 (2) | 1 (<1) | |
| Missing | 10 (<1) | 1 (<1) | |
| Time to HCT from diagnosis, mo | 23 (<1-608) | 27 (4-281) | .03 |
| Time to HCT from diagnosis, mo | .12 | ||
| 0-12 | 316 (26) | 41 (21) | |
| 12-36 | 496 (41) | 75 (39) | |
| ≥36 | 391 (32) | 74 (39) | |
| Missing | 1 (<1) | 1 (<1) | |
| Donor-related | |||
| Donor type | .29 | ||
| HLA-identical sibling | 539 (45) | 73 (38) | |
| Well-matched unrelated | 447 (37) | 85 (45) | |
| Partially matched unrelated | 125 (10) | 21 (11) | |
| Mismatched unrelated | 9 (<1) | 2 (1) | |
| Unrelated (matching indeterminable) | 84 (7) | 10 (5) | |
| URD-recipient HLA-matching | .10 | ||
| 3 | 0 | 1 (<1) | |
| 5 | 1 (<1) | 0 | |
| 6 | 5 (<1) | 0 | |
| 7 | 101 (15) | 19 (16) | |
| 8 | 407 (61) | 79 (67) | |
| Missing | 151 (23) | 19 (16) | |
| Donor-recipient sex match | .003 | ||
| M-M | 456 (38) | 63 (33) | |
| M-F | 271 (23) | 66 (35) | |
| F-M | 264 (22) | 27 (14) | |
| F-F | 209 (17) | 34 (18) | |
| Missing | 4 (<1) | 1 (<1) | |
| Donor-recipient CMV status | .36 | ||
| +/+ | 377 (31) | 67 (35) | |
| +/− | 99 (8) | 18 (9) | |
| −/+ | 272 (23) | 47 (25) | |
| −/− | 287 (24) | 41 (21) | |
| URD age, median (range), y | 30 (18-61) | 29 (20-59) | .22 |
| URD age, y | .15 | ||
| 18-29 | 271 (41) | 59 (50) | |
| 30-39 | 137 (21) | 27 (23) | |
| 40-49 | 103 (15) | 17 (14) | |
| 50-59 | 37 (6) | 2 (2) | |
| ≥60 | 2 (<1) | 0 | |
| Missing | 115 (17) | 13 (11) | |
| Transplant related | |||
| Year of transplant | .08 | ||
| 2007-2008 | 261 (22) | 30 (16) | |
| 2009-2010 | 311 (26) | 60 (31) | |
| 2011-2012 | 302 (25) | 56 (29) | |
| 2013-2014 | 330 (27) | 45 (24) | |
| Graft type | .58 | ||
| BM | 293 (24) | 43 (23) | |
| PB | 911 (76) | 148 (77) | |
| Conditioning regimen | |||
| TBI ± Cy ± others (376; 31%) | Bu2 + Flu ± others (97; 51%) | ||
| Bu + Cy ± others (492; 41%) | Flu + Mel ± other (53; 28%) | ||
| Bu4 + Flu ± others (302; 25%) | Cy ± Flu ± TBI ± others (18; 9%) | ||
| Others (34; 3%) | TBI ± Flu ± others (11; 6%) | ||
| Others (12; 6%) | |||
| ATG/alemtuzumab | <.001 | ||
| ATG alone | 258 (21) | 72 (38) | |
| Alemtuzumab alone | 15 (1) | 18 (9) | |
| No ATG or alemtuzumab | 929 (77) | 101 (53) | |
| Missing | 2 (<1) | 0 | |
| GVHD prophylaxis | .26 | ||
| Ex vivo T-cell depletion/CD34 selection | 20 (2) | 1 (<1) | |
| TAC based | 712 (59) | 124 (65) | |
| CSA based | 414 (34) | 55 (29) | |
| Other | 53 (4) | 11 (6) | |
| Missing | 5 (<1) | 0 |
| Variable . | MAC (n = 1204) . | RIC (n = 191) . | P . |
|---|---|---|---|
| Follow-up of survivors, median (range), mo | 52 (4-102) | 60 (7-101) | |
| Number of centers | 163 | 76 | |
| Patient related | |||
| Age at transplant, median (range), y | 43 (18-60) | 51 (19-60) | <.001 |
| Age at transplant, y | <.001 | ||
| 18-29 | 212 (18) | 17 (9) | |
| 30-39 | 276 (23) | 21 (11) | |
| 40-49 | 404 (34) | 47 (25) | |
| 50-59 | 312 (26) | 106 (55) | |
| Sex | <.001 | ||
| Male | 722 (60) | 90 (47) | |
| Female | 482 (40) | 101 (53) | |
| KPS, % | <.001 | ||
| 90-100 | 845 (70) | 110 (58) | |
| <90 | 267 (22) | 72 (38) | |
| Missing | 92 (8) | 9 (5) | |
| WHO region | .60 | ||
| Africa | 1 (<1) | 0 | |
| Americas | 1054 (88) | 172 (90) | |
| Eastern Mediterranean | 22 (2) | 0 | |
| Europe | 78 (6) | 10 (5) | |
| Southeastern Asian | 21 (2) | 4 (2) | |
| Western Pacific | 27 (2) | 5 (3) | |
| Missing | 1 (<1) | 0 | |
| Sorror comorbidity index (HCT-CI) | .003 | ||
| 0 | 525 (44) | 64 (34) | |
| 1 | 132 (11) | 27 (14) | |
| 2 | 125 (10) | 25 (13) | |
| 3+ | 246 (20) | 58 (30) | |
| Missing | 176 (15) | 17 (9) | |
| Disease related | |||
| Disease status prior to transplant | .20 | ||
| CP1 | 504 (42) | 92 (48) | |
| AP | 405 (34) | 60 (31) | |
| CP2+ | 278 (23) | 38 (20) | |
| CP, NOS | 17 (1) | 1 (<1) | |
| Prior treatment | .85 | ||
| No | 9 (<1) | 1 (<1) | |
| Yes | 1185 (98) | 189 (99) | |
| Missing | 10 (<1) | 1 (<1) | |
| Use of TKI prior to HCT | .89 | ||
| No | 73 (6) | 11 (6) | |
| Yes | 1121 (93) | 179 (94) | |
| Missing | 10 (<1) | 1 (<1) | |
| TKI used pre-HCT | .11 | ||
| No TKI used | 73 (6) | 11 (6) | |
| Imatinib + dasatinib + nilotinib | 250 (21) | 52 (27) | |
| Imatinib + dasatinib | 295 (25) | 55 (29) | |
| Imatinib + nilotinib | 73 (6) | 13 (7) | |
| Dasatinib + nilotinib | 35 (3) | 8 (4) | |
| Imatinib | 395 (33) | 43 (23) | |
| Dasatinib | 52 (4) | 7 (4) | |
| Nilotinib | 21 (2) | 1 (<1) | |
| Missing | 10 (<1) | 1 (<1) | |
| Time to HCT from diagnosis, mo | 23 (<1-608) | 27 (4-281) | .03 |
| Time to HCT from diagnosis, mo | .12 | ||
| 0-12 | 316 (26) | 41 (21) | |
| 12-36 | 496 (41) | 75 (39) | |
| ≥36 | 391 (32) | 74 (39) | |
| Missing | 1 (<1) | 1 (<1) | |
| Donor-related | |||
| Donor type | .29 | ||
| HLA-identical sibling | 539 (45) | 73 (38) | |
| Well-matched unrelated | 447 (37) | 85 (45) | |
| Partially matched unrelated | 125 (10) | 21 (11) | |
| Mismatched unrelated | 9 (<1) | 2 (1) | |
| Unrelated (matching indeterminable) | 84 (7) | 10 (5) | |
| URD-recipient HLA-matching | .10 | ||
| 3 | 0 | 1 (<1) | |
| 5 | 1 (<1) | 0 | |
| 6 | 5 (<1) | 0 | |
| 7 | 101 (15) | 19 (16) | |
| 8 | 407 (61) | 79 (67) | |
| Missing | 151 (23) | 19 (16) | |
| Donor-recipient sex match | .003 | ||
| M-M | 456 (38) | 63 (33) | |
| M-F | 271 (23) | 66 (35) | |
| F-M | 264 (22) | 27 (14) | |
| F-F | 209 (17) | 34 (18) | |
| Missing | 4 (<1) | 1 (<1) | |
| Donor-recipient CMV status | .36 | ||
| +/+ | 377 (31) | 67 (35) | |
| +/− | 99 (8) | 18 (9) | |
| −/+ | 272 (23) | 47 (25) | |
| −/− | 287 (24) | 41 (21) | |
| URD age, median (range), y | 30 (18-61) | 29 (20-59) | .22 |
| URD age, y | .15 | ||
| 18-29 | 271 (41) | 59 (50) | |
| 30-39 | 137 (21) | 27 (23) | |
| 40-49 | 103 (15) | 17 (14) | |
| 50-59 | 37 (6) | 2 (2) | |
| ≥60 | 2 (<1) | 0 | |
| Missing | 115 (17) | 13 (11) | |
| Transplant related | |||
| Year of transplant | .08 | ||
| 2007-2008 | 261 (22) | 30 (16) | |
| 2009-2010 | 311 (26) | 60 (31) | |
| 2011-2012 | 302 (25) | 56 (29) | |
| 2013-2014 | 330 (27) | 45 (24) | |
| Graft type | .58 | ||
| BM | 293 (24) | 43 (23) | |
| PB | 911 (76) | 148 (77) | |
| Conditioning regimen | |||
| TBI ± Cy ± others (376; 31%) | Bu2 + Flu ± others (97; 51%) | ||
| Bu + Cy ± others (492; 41%) | Flu + Mel ± other (53; 28%) | ||
| Bu4 + Flu ± others (302; 25%) | Cy ± Flu ± TBI ± others (18; 9%) | ||
| Others (34; 3%) | TBI ± Flu ± others (11; 6%) | ||
| Others (12; 6%) | |||
| ATG/alemtuzumab | <.001 | ||
| ATG alone | 258 (21) | 72 (38) | |
| Alemtuzumab alone | 15 (1) | 18 (9) | |
| No ATG or alemtuzumab | 929 (77) | 101 (53) | |
| Missing | 2 (<1) | 0 | |
| GVHD prophylaxis | .26 | ||
| Ex vivo T-cell depletion/CD34 selection | 20 (2) | 1 (<1) | |
| TAC based | 712 (59) | 124 (65) | |
| CSA based | 414 (34) | 55 (29) | |
| Other | 53 (4) | 11 (6) | |
| Missing | 5 (<1) | 0 |
Data are presented as n (%) of patients unless otherwise indicated.
ATG, anti-thymocyte globulin; BM, bone marrow; CP, chronic phase; CSA, cyclosporine; Cy; cyclophosphamide; F, female; Flu, fludarabine; M, male; NOS, not otherwise specified; PB, peripheral blood; TAC, tacrolimus; URD; unrelated donor; WHO, World Health Organization.